MUC1-DC

MUC1-DC is an autologous dendritic cell therapy in which patient-derived dendritic cells are pulsed, loaded, or fused with antigens derived from the tumor-associated protein MUC1[2]. MUC1 is a highly glycosylated transmembrane protein overexpressed on various cancers including lung, breast, pancreatic, ovarian, and prostate tumors[3][1]. Dendritic cells loaded with MUC1 aim to induce a tumor-specific immune response by presenting MUC1 epitopes to T cells, thereby overcoming cancer-induced immunosuppression and triggering cytotoxic T lymphocyte-mediated tumor killing[1][2]. This immunotherapy is under investigation as a treatment for multiple solid cancers, particularly epithelial malignancies, and has shown efficacy in preclinical studies and early clinical trials by reversing MUC1 tolerance, activating cytotoxic T cells, and prolonging survival[1][2][3][5].

Brand names

MUC1-DCMUC-1-DCMUC 1-DC

Other names

MUC1 dendritic cell vaccineMUC-1 dendritic cell vaccineMUC 1 dendritic cell vaccineMUC1-pulsed DCMUC-1-pulsed DCMUC 1-pulsed DCMUC1-loaded dendritic cell vaccineMUC-1-loaded dendritic cell vaccineMUC 1-loaded dendritic cell vaccine